Eydisbio Inc.
Tuesday, June 04, 2024
Orphan and Rare Disease
Company Presentation Theater 4
EydisBio is an emerging pharmaceutical company located in Durham, NC. EydisBio is focused on developing small molecule inhibitors towards difficult to treat diseases. Our primary program has focused on developing selective TAK1 inhibitors for the treatment of autoimmune diseases such as systemic sclerosis and rheumatoid arthritis. Our team of experienced drug developers help guide our program and have demonstrated great success in being the first group to selectively target TAK1 therapeutically in pre-clinical models. Our pioneering studies have shown the therapeutic potential of TAK1 in pre-clinical models and our immediate goal is to advance a lead candidate towards first in human studies.
Company Website:
http://www.eydisbio.com
Lead Product in Development:
TAK1 inhibitor for autoimmune disease
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Company HQ City
Durham
Company HQ State
North Carolina
Company HQ Country
United States
CEO/Top Company Official
Timothy Haystead PhD
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
Selective small molecule targeting of TAK1/TNF signaling in systemic sclerosis
EydisBio Inc.
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())